Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/oby.23232 http://scihub22266oqcxt.onion/10.1002/oby.23232 34028990!8242726!34028990     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Obesity+(Silver+Spring) 2021 ; 29 (9): 1427-1433 Nephropedia Template TP {{tp|p=34028990|t=2021. Epicardial fat inflammation response to COVID-19 therapies |pdf=|usr=}}{{34028990}} gab.com Text Epicardial fat inflammation response to COVID-19 therapies JO: Obesity (Silver Spring) http://www.kidney.de/pget.php?&tw=1&pmid=34028990 #FOAvip OBJECTIVE: Adipose tissue plays a role in the novel coronavirus disease 2019 (COVID-19). Epicardial adipose tissue (EAT), a unique visceral fat, presents with a high degree of inflammation in severe COVID-19. Whether and how adipose tissue may respond to the COVID-19 therapies is unknown. METHODS: The difference in computed tomography-measured EAT and subcutaneous (SAT) attenuation, defined as mean attenuation expressed in Hounsfield units (HU), was retrospectively analyzed in 72 patients (mean [SD] age was 59.6 [12.4] years, 50 patients [69%] were men) at the hospital admission for COVID-19 and 99 days (interquartile range = 71-129) after discharge. RESULTS: At the admission, EAT-HU was significantly correlated with blood glucose levels, interleukin 6, troponin T levels, and waist circumference. EAT-HU decreased from -87.21 (16.18) to -100.0 (11) (p < 0.001), whereas SAT-HU did not change (-110.21 [12.1] to -111.11 [27.82]; p = 0.78) after therapy. Changes in EAT-HU (expressed as ?) significantly correlated with dexamethasone therapy (r = -0.46, p = 0.006) and when dexamethasone was combined with tocilizumab (r = -0.24, p = 0.04). CONCLUSIONS: Dexamethasone therapy was associated with significant reduction of EAT inflammation in COVID-19 patients, whereas SAT showed no changes. Anti-inflammatory therapies targeting visceral fat may be helpful in COVID-19. Twit Text FOAVip Epicardial fat inflammation response to COVID-19 therapies ????Obesity (Silver Spring) http://www.kidney.de/pget.php?&tw=1&pmid=34028990 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34028990 #FOAvip English Wikipedia <ref>{{Cite pmid|34028990}}</ref> Epicardial fat inflammation response to COVID-19 therapies #MMPMID34028990 Iacobellis G; Malavazos AE; Basilico S; Tresoldi S; Rinaldo RF; Dubini C; Capitanio G; Serpi F; Schiaffino S; Oliva OA; Cariati M; Morricone L; Centanni S; Sardanelli F; Carruba M; Corsi Romanelli MM; Secchi F Obesity (Silver Spring) 2021[Sep]; 29 (9): 1427-1433 PMID34028990show ga OBJECTIVE: Adipose tissue plays a role in the novel coronavirus disease 2019 (COVID-19). Epicardial adipose tissue (EAT), a unique visceral fat, presents with a high degree of inflammation in severe COVID-19. Whether and how adipose tissue may respond to the COVID-19 therapies is unknown. METHODS: The difference in computed tomography-measured EAT and subcutaneous (SAT) attenuation, defined as mean attenuation expressed in Hounsfield units (HU), was retrospectively analyzed in 72 patients (mean [SD] age was 59.6 [12.4] years, 50 patients [69%] were men) at the hospital admission for COVID-19 and 99 days (interquartile range = 71-129) after discharge. RESULTS: At the admission, EAT-HU was significantly correlated with blood glucose levels, interleukin 6, troponin T levels, and waist circumference. EAT-HU decreased from -87.21 (16.18) to -100.0 (11) (p < 0.001), whereas SAT-HU did not change (-110.21 [12.1] to -111.11 [27.82]; p = 0.78) after therapy. Changes in EAT-HU (expressed as ?) significantly correlated with dexamethasone therapy (r = -0.46, p = 0.006) and when dexamethasone was combined with tocilizumab (r = -0.24, p = 0.04). CONCLUSIONS: Dexamethasone therapy was associated with significant reduction of EAT inflammation in COVID-19 patients, whereas SAT showed no changes. Anti-inflammatory therapies targeting visceral fat may be helpful in COVID-19. |*COVID-19 Drug Treatment[MESH] |*Intra-Abdominal Fat/diagnostic imaging[MESH] |*Pericardium/diagnostic imaging[MESH] |Aged[MESH] |Antibodies, Monoclonal, Humanized/therapeutic use[MESH] |Dexamethasone/*therapeutic use[MESH] |Female[MESH] |Humans[MESH] |Inflammation[MESH] |Male[MESH] |Middle Aged[MESH]Epicardial fat inflammation response to COVID-19 therapies (epmc).pdf DeepDyve Pubget Overpricing